机构：[1]Xingtai Peoples Hosp, Dept Breast Surg, Xingtai, Hebei, Peoples R China[2]Hebei Med Univ, Dept Breast Ctr, Hosp 4, Jiankanglu 12, Shijiazhuang 050011, Hebei, Peoples R China临床科室外一科河北医科大学第四医院[3]Tangshan Peoples Hosp, Dept Breast Surg, Tangshan, Hebei, Peoples R China[4]First Hosp Qinhuangdao, Dept Breast Surg, Qinhuangdao, Hebei, Peoples R China
Objective To evaluate the efficacy and safety of the combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer (BC) in patients with axillary lymph node metastasis. Methods In this single-arm study, 91 patients with clinical stage IIA-IIIc breast cancer received six cycles of pegylated liposomal doxorubicin plus docetaxel as neoadjuvant chemotherapy (NAC). Trastuzumab was allowed for patients with human epidermal growth factor receptor 2-positive tumors. The primary endpoint was pathologic complete response (pCR) in the breast after surgery. The overall response rate (ORR), Miller-Payne (MP) score of the primary tumors, and incidence of adverse events were also evaluated. Results In total, 88 patients completed all cycles of NAC. Fourteen patients (15.4%, 95% confidence interval [CI] = 7.8-22.9) achieved pCR. The ORR was 89% (95% CI = 82.5-95.6), and 72 lesions (79.1%) were rated as MP grade 3 or higher. The left ventricular ejection fraction (LVEF) was within the normal range, although four (4.4%) patients experienced an LVEF decline exceeding 10%. No symptomatic cardiac events were reported. Conclusion Preoperative NAC with pegylated liposomal doxorubicin and docetaxel appears effective and safe for treating BC with axillary lymph node metastasis.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2020]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
JCR分区：
出版当年[2020]版：
Q4PHARMACOLOGY & PHARMACYQ4MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版：
Q3MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
第一作者机构：[1]Xingtai Peoples Hosp, Dept Breast Surg, Xingtai, Hebei, Peoples R China
通讯作者：
通讯机构：[2]Hebei Med Univ, Dept Breast Ctr, Hosp 4, Jiankanglu 12, Shijiazhuang 050011, Hebei, Peoples R China[*1]Department of Breast Center, the Fourth Hospital of Hebei Medical University, Jiankanglu 12, Shijiazhuang 050011, Hebei, China.
推荐引用方式(GB/T 7714)：
Wang Li,Hong Yang,Ma Jie,et al.Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis[J].JOURNAL OF INTERNATIONAL MEDICAL RESEARCH.2020,48(8):doi:10.1177/0300060520944310.
APA：
Wang, Li,Hong, Yang,Ma, Jie,Han, Meng,Zhang, Shuo...&Liu, Yunjiang.(2020).Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis.JOURNAL OF INTERNATIONAL MEDICAL RESEARCH,48,(8)
MLA：
Wang, Li,et al."Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis".JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 48..8(2020)
